Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jul 11, 2022

Keywords

ClinConnect Summary

The ANCHOR-Prostate trial is studying a new treatment approach for men with metastatic prostate cancer, which is cancer that has spread beyond the prostate. Specifically, the trial is looking at a type of radiotherapy called SABR (Stereotactic Ablative Body Radiotherapy) to see if it can help improve the time patients stay free from cancer progression after they have responded well to standard treatments. In this study, 80 participants will be chosen at random to receive this new treatment, and researchers will track how well it works over the course of one year.

To be eligible for the trial, participants must already be part of a related study, have metastatic prostate cancer that hasn't progressed despite treatment (measured by stable PSA levels), and have a specific number of detectable cancer sites that can be targeted with SABR. Men aged 18 and older with varying levels of health can participate. If you join the trial, you can expect regular check-ups and monitoring, and you will be contributing to important research that could lead to better treatment options for prostate cancer in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 3.1.1 Enrolled in PERa (CHUM CER 17.032) and randomly selected for AnChoR-Prostate.
• • 3.1.2 Diagnosis of metastatic prostate cancer having achieved maximum PSA response to SOC systemic therapy defined as two consecutive stable PSA within 6 months of regimen start. Stable PSA is defined as non- progressing (\<25% rise from nadir, per PCWG3 guidelines).
• • 3.1.3 ECOG 0-2 3.1.4 PSA \> 0.2 ng/mL 3.1.5 1-5 sites of PSMA-PET avid disease amenable to SABR.
• Exclusion Criteria:
• • none